PROTACs: A Paradigm Shift in Drug Discovery – Module 3

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (3 of 5 Modules)

This activity provides an overview of emerging data in the development of proteolysis targeting chimeras (PROTACs) that harness intracellular E3-ubiquitin ligases for the treatment of hematologic malignancies.

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Describe emerging proteolysis targeting chimeras (PROTACs) under investigation for the treatment of hematologic malignancies

Activity Faculty

Katherine Donovan, PhD

Lead Scientist, Department of Cancer Biology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Featured RMEI CE Activities – Earn CE Credit(s)

Immunotherapy for NMSC: Key Insights for Oncology, Dermatology, and Infusion Nurses: A Clinical Transfers®

1.0 CE Credit(s)

Beyond the Guidelines for CMV: Clinical Perspectives on Challenging Cases Post-Transplant

1.5 CE Credit(s)

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management

Hybrid Symposium

Privacy | Terms of Use